Determine the necessary mass, volume, or concentration for preparing a solution.
BDP9066 - 10mM in DMSO , CAS No.2226507-04-4
DISPONIBLE À COMMANDE
GRADE & PURITY 10mM in DMSO
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
224,000+ produits de recherche · Triple ISO certified · COA & SDS disponible pour chaque produit · Expédition le jour même sur les articles en stock
Why this grade
10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 1 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Vue d’ensemble
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC 50 of 64 nM for MRCKβ in SCC12 cells, K i values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.
In Vitro
BDP9066 shows antiproliferative effects with greatest activity in hematologic cancer cells. BDP9066 inhibits MLC phosphorylation and blocks SCC12 squamous cell carcinoma motility and invasion. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
BDP9066 topical application significantly decreases phosphorylated MRCKα S1003 staining and tumor volumes . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:IC50: 64 nM (MRCKβ in SCC12 cells), Ki: 0.0136 nM/0.0233 nM (MRCKα/β)
Specifications
Spécifications et pureté
10mM in DMSO
Mécanismes biochimiques et physiologiques
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC 50 of 64 nM for MRCKβ in SCC12 cells, K i values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeu
Conditions de stockage de stockage
Store at -80°C
Expédié en
Dry ice packs + Cold packs
Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.
Type d'action
INHIBITOR
Noms et identifiants
| PubChem CID | 132275018 |
|---|---|
| Termes d'entrée MeSH | (6S)-8-(3-(4-Pyrimidinyl)-7H-pyrrolo(2,3-b)pyridin-4-yl)-1,8-diazaspiro(5.5)undecane;1,8-Diazaspiro(5.5)undecane, 8-(3-(4-pyrimidinyl)-7H-pyrrolo(2,3-b)pyridin-4-yl)-, (6S)-;BDP9066 |
| Poids moléculaire | 348.44 |
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Citations of This Product
Références
| 1. Sufang Xu, Xin Zhang, Jingru Sun, Man Qin, Huarong Du, Bing Luo. (2026) Macrophage-Derived Transcriptional Signatures Predict Prognosis and Drug Sensitivity in Thyroid Cancer: Integrative Analysis and Experimental Validation of SMYD3. ImmunoTargets and Therapy, [PMID:] [10.2147/ITT.S565624] |
Calculateurs de solution
Avis
Avis des clients
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.